Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT06592014
PHASE1/PHASE2

Lithium for Parkinson's: an Extension Trial

Sponsor: State University of New York at Buffalo

View on ClinicalTrials.gov

Summary

This study will examine the effects of 24 weeks of lithium therapy achieving serum lithium levels of 0.25-0.50mmol/L on MRI and blood-based biomarkers in Parkinson's disease patients who have completed one of our current 24-week lithium clinical trials.

Official title: Repurposing Lithium as a Disease-modifying Therapy in Parkinson's Disease: an Open-label Extension Trial.

Key Details

Gender

All

Age Range

45 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

35

Start Date

2024-08-09

Completion Date

2026-11-01

Last Updated

2025-11-19

Healthy Volunteers

No

Interventions

DIETARY_SUPPLEMENT

Lithium aspartate

Lithium aspartate with dosage adjusted to serum lithium level 0.25-0.50mmol/L

Locations (1)

UBMD Neurology

Williamsville, New York, United States